Form 8-K Greenpro Capital Corp. For: Oct 28
- S&P 500 and Nasdaq notch highest closes since early 2022
- U.S. economy adds 199,000 jobs in November
- Fed should 'lowball' rate cuts expectations next week says analyst after strong jobs data
- Bernstein's best idea for 2024? Short Tesla stock
- Analysts defend Broadcom as annual guidance falls short after FQ4 earnings beat
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act 1934
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or Other Jurisdiction
(Address of Principal Executive Offices)
telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|Title of Each Class||Trading Symbol(s)||Name of Each Exchange on Which Registered|
Item 5.07 Submission of Matters to a Vote of Security Holders.
On October 28, 2022, Greenpro Capital Corp. (the “Company”) held its Annual Meeting of Stockholders to vote on the following matters:
1. Election of Directors
Stockholders elected all of the Company’s nominees for director for one-year terms expiring on the date of the Annual Meeting in 2023, in accordance with the voting results listed below.
|Nominee Name||Votes For||Votes Withheld||Abstentions |
and Broker Non-Votes
|Lee, Chong Kuang||3,583,924||72,471||1,216,257|
|Loke Che Chan Gilbert||3,583,823||72,572||1,216,257|
|Louis, Ramesh Ruben||3,583,449||72,946||1,216,257|
|Glendening, Brent Lewis||3,583,450||72,945||1,216,257|
|Bringuier, Christophe Philippe Roland||3,583,514||72,881||1,216,257|
2. Ratification of the Company’s Independent Registered Public Accounting Firm
Stockholders ratified the appointment of JP Centurion & Partners PLT as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, in accordance with the voting results listed below.
3. Advisory Vote on Executive Compensation
Stockholders approved the compensation paid to the Company’s named executive officers as disclosed in the 2022 Proxy Statement under “Executive Compensation” on an advisory basis, in accordance with the voting results listed below.
4. Advisory Vote on Frequency of Advisory Vote on Executive Compensation
|1 year||2 years||3 years||Abstain||Broker Non-Votes|
In light of the foregoing vote regarding Proposal 4, the Company has decided to include an advisory stockholder vote on the compensation of executives in its proxy materials every three years.
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|GREENPRO CAPITAL CORP.|
|By:||/s/ Lee Chong Kuang|
|Name:||Lee Chong Kuang|
|Title:||President and Chief Executive Officer|
Dated: October 28, 2022
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flash News: OKX to change funding fee collection mechanism
- Research Reveals Opportunities to Better Address Blood Disorders Early in Life
- ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!